JP7672122B2 - 生物活性複合体の調製 - Google Patents

生物活性複合体の調製 Download PDF

Info

Publication number
JP7672122B2
JP7672122B2 JP2019563219A JP2019563219A JP7672122B2 JP 7672122 B2 JP7672122 B2 JP 7672122B2 JP 2019563219 A JP2019563219 A JP 2019563219A JP 2019563219 A JP2019563219 A JP 2019563219A JP 7672122 B2 JP7672122 B2 JP 7672122B2
Authority
JP
Japan
Prior art keywords
salt
peptide
polypeptide
phosphate
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019563219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519673A (ja
JP2020519673A5 (OSRAM
Inventor
アフターブ ナディーム，
カタリナ スヴァンボルグ，
チン シン ホ，
Original Assignee
ハムレット・ファルマ・アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハムレット・ファルマ・アーベー filed Critical ハムレット・ファルマ・アーベー
Publication of JP2020519673A publication Critical patent/JP2020519673A/ja
Publication of JP2020519673A5 publication Critical patent/JP2020519673A5/ja
Priority to JP2023040807A priority Critical patent/JP7705160B2/ja
Application granted granted Critical
Publication of JP7672122B2 publication Critical patent/JP7672122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Inorganic Chemistry (AREA)
JP2019563219A 2017-05-14 2018-05-14 生物活性複合体の調製 Active JP7672122B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023040807A JP7705160B2 (ja) 2017-05-14 2023-03-15 生物活性複合体の調製

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1707715.7 2017-05-14
GBGB1707715.7A GB201707715D0 (en) 2017-05-14 2017-05-14 Preperation of biologically active complexes
PCT/EP2018/062396 WO2018210759A1 (en) 2017-05-14 2018-05-14 Preparation of biologically active complexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023040807A Division JP7705160B2 (ja) 2017-05-14 2023-03-15 生物活性複合体の調製

Publications (3)

Publication Number Publication Date
JP2020519673A JP2020519673A (ja) 2020-07-02
JP2020519673A5 JP2020519673A5 (OSRAM) 2021-07-26
JP7672122B2 true JP7672122B2 (ja) 2025-05-07

Family

ID=59201543

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019563219A Active JP7672122B2 (ja) 2017-05-14 2018-05-14 生物活性複合体の調製
JP2023040807A Active JP7705160B2 (ja) 2017-05-14 2023-03-15 生物活性複合体の調製

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023040807A Active JP7705160B2 (ja) 2017-05-14 2023-03-15 生物活性複合体の調製

Country Status (13)

Country Link
US (3) US20200140481A1 (OSRAM)
EP (2) EP3811967B1 (OSRAM)
JP (2) JP7672122B2 (OSRAM)
KR (2) KR20260021814A (OSRAM)
CN (2) CN119700935A (OSRAM)
AU (1) AU2018269304B2 (OSRAM)
CA (1) CA3063285A1 (OSRAM)
DK (2) DK3618848T3 (OSRAM)
ES (2) ES2861252T3 (OSRAM)
FI (1) FI3811967T3 (OSRAM)
GB (1) GB201707715D0 (OSRAM)
PL (2) PL3618848T3 (OSRAM)
WO (1) WO2018210759A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201621752D0 (en) * 2016-12-20 2017-02-01 Hamlet Pharma Ab Therapeutically active complexes
GB201707715D0 (en) * 2017-05-14 2017-06-28 Hamlet Pharma Ab Preperation of biologically active complexes
WO2019243547A1 (en) * 2018-06-20 2019-12-26 Hamlet Pharma Ab Therapeutically active complexes
GB2574845A (en) * 2018-06-20 2019-12-25 Hamlet Pharma Ab Therapeutically active complexes
WO2021032807A1 (en) * 2019-08-20 2021-02-25 Hamlet Pharma Ab Combination of a chemotherapeutic agent and alpha-lactoglubulin-oleic acid complex for cancer therapy
GB202015836D0 (en) * 2020-10-06 2020-11-18 Hamlet Pharma Ab Compositions
CN120239612A (zh) 2022-10-03 2025-07-01 林南制药公司 一种用于治疗或预防癌症的包含α-乳清蛋白和脂肪酸或脂质的复合物
GB202303177D0 (en) 2023-03-03 2023-04-19 Linnane Pharma Ab Method of predicting response to treatment
WO2025186107A1 (en) 2024-03-04 2025-09-12 Linnane Pharma Ab Therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550263B2 (en) * 2003-09-05 2009-06-23 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
US8796218B2 (en) 2009-01-09 2014-08-05 Hamlet Pharma Ab Complex and production process
WO2010131237A1 (en) 2009-05-13 2010-11-18 Agriculture And Food Development Authority (Teagasc) A process for producing a biologically active globular protein complex
GB0908279D0 (en) 2009-05-14 2009-06-24 Enovate Systems Ltd Subsea winch
EP2643010B1 (en) 2010-11-24 2016-11-16 HAMLET Pharma AB Biologically active complex and its preparation
HUE038910T2 (hu) * 2012-08-09 2018-12-28 Hamlet Pharma Ab Profilaktikus és gyógytáp terápia
GB201621752D0 (en) * 2016-12-20 2017-02-01 Hamlet Pharma Ab Therapeutically active complexes
GB201707715D0 (en) 2017-05-14 2017-06-28 Hamlet Pharma Ab Preperation of biologically active complexes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biochem. Biophys. Res. Commun. (2008) vol.376, issue 1, p.211-214

Also Published As

Publication number Publication date
DK3811967T5 (da) 2024-08-19
JP2023075290A (ja) 2023-05-30
DK3618848T3 (da) 2021-03-01
EP3811967B1 (en) 2023-12-20
JP7705160B2 (ja) 2025-07-09
ES2973290T3 (es) 2024-06-19
PL3618848T3 (pl) 2021-06-14
AU2018269304A1 (en) 2019-11-21
WO2018210759A1 (en) 2018-11-22
PL3811967T3 (pl) 2024-03-18
KR20260021814A (ko) 2026-02-13
JP2020519673A (ja) 2020-07-02
EP3618848A1 (en) 2020-03-11
KR20200015557A (ko) 2020-02-12
CN110650746B (zh) 2024-12-31
ES2861252T3 (es) 2021-10-06
US12331073B2 (en) 2025-06-17
CA3063285A1 (en) 2018-11-22
EP3811967A1 (en) 2021-04-28
AU2018269304B2 (en) 2025-02-27
GB201707715D0 (en) 2017-06-28
US20260085088A1 (en) 2026-03-26
US20210130394A1 (en) 2021-05-06
FI3811967T3 (fi) 2023-12-28
EP3618848B1 (en) 2020-11-25
CN119700935A (zh) 2025-03-28
CN110650746A (zh) 2020-01-03
US20200140481A1 (en) 2020-05-07
DK3811967T3 (da) 2024-01-08

Similar Documents

Publication Publication Date Title
JP7705160B2 (ja) 生物活性複合体の調製
US20160115200A1 (en) New Use for JNK Inhibitor Molecules for Treatment of Various Diseases
JP2023545152A (ja) アンフォールディングタンパク質を含む組成物の調製方法
KR102545825B1 (ko) 흥분성 신경 독성 관련 손상 치료를 위한 펩타이드 조성물
PT2285416E (pt) Conjugados para o tratamento de mesotelioma
JP2021514183A (ja) 改変免疫調節ペプチド
CN106659764A (zh) 环状鞘脂激活蛋白原肽及其用途
KR102923786B1 (ko) Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 제제
HK40050699A (en) Preparation of biologically active complexes
HK40050699B (en) Preparation of biologically active complexes
HK40025666B (en) Biologically active complexes and therapeutic uses thereof
HK40025666A (en) Biologically active complexes and therapeutic uses thereof
WO2016099409A1 (en) Use of one or more antimicrobial peptides to induce cell death in various types of cancers
JP2022545429A (ja) がん治療のための化学療法剤とα－ラクトグロブリン－オレイン酸複合体との組合せ
CN109734779B (zh) 一种靶向Tie-1的多肽及其应用
CN116157142A (zh) 肽、肽的盐、药物组合物和生物体组织钙化抑制剂
Yeo et al. Nanoscale Horizons
US20050239703A1 (en) Anticancer peptide compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200107

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20200107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230315

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230315

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230323

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230328

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230421

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250415

R150 Certificate of patent or registration of utility model

Ref document number: 7672122

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150